Pacira Pharmaceuticals has submitted a Prior Approval Supplement (PAS) with the FDA for an additional bulk manufacturing suite for Exparel (bupivacaine liposome injectable suspension). Under the reauthorization of the Prescription Drug User Fee Act (PDUFA), the FDA established a four-month PDUFA goal for approval of a manufacturing PAS. Should the FDA accept the PAS for review, a PDUFA date in early April 2014 is anticipated. Exparel is manufactured at the Pacira FDA-approved Science Center Cam...